Pure And Gentle Mineral Oil (mineral oil)

Dosage of mineral oil emulsion is expressed in terms of its mineral oil content. Oral mineral oil preparations should be used only occasionally and should not be administered for longer than 1 week.

The usual oral dosage of mineral oil for adults and children 12 years of age and older is 15-45 mL daily given as a single dose (minimum dose of 15 mL) or in divided doses. For children 6-11 years of age, the usual oral dosage of mineral oil is 5-15 mL daily given as a single dose (minimum of 5 mL) or in divided doses.

Mineral oil enemas are administered rectally in a usual dosage of 120 mL (range: 60-150 mL) daily given as a single dose in adults and children 12 years of age and older and 30-60 mL for children 2-11 years of age.

Mineral oil or mineral oil emulsion is administered orally. Although mineral oil emulsions penetrate and soften fecal material more effectively and are more palatable than plain mineral oil, there appears to be little difference in laxative effectiveness between these two preparations. Mineral oil also may be administered rectally as an enema. Plain (nonemulsified) mineral oil should be administered only at bedtime on an empty stomach. Mineral oil emulsion may be administered with meals. Containers of mineral oil emulsion should be shaken before using.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

Laxatives/Trofinetide

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: Trofinetide commonly causes diarrhea of mild to moderate severity. Laxatives may increase the incidence or severity of diarrhea.(1)

CLINICAL EFFECTS: Concurrent use of laxatives with trofinetide may increase the risk of severe diarrhea.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Patients should stop laxatives before starting trofinetide. If diarrhea occurs, consider anti-diarrheal treatment and monitor hydration status. If severe diarrhea or dehydration occurs, interrupt, reduce dose, or discontinue trofinetide.(1)

DISCUSSION: In clinical trials, 85% of patients on trofinetide developed diarrhea. Concurrent use of laxatives may increase this risk.(1)

Laxatives; Stool Softeners/Tenapanor

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: Tenapanor commonly causes diarrhea of mild to moderate severity. Laxatives and stool softeners may increase the incidence or severity of diarrhea.(1)

CLINICAL EFFECTS: Concurrent use of laxatives or stool softeners with tenapanor may increase the risk of severe diarrhea.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The US manufacturer of tenapanor states that patients should be instructed to avoid stool softeners and laxatives with tenapanor. If severe diarrhea occurs, tenapanor should be discontinued.(1)

DISCUSSION: In clinical trials, 43-53% of CKD patients on dialysis treated with tenapanor developed diarrhea. Diarrhea usually occurred soon after treatment initiation and was severe in 5% of patients.(1)

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

• Bed-ridden
• Gastrointestinal obstruction

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

Less Frequent

• Perianal irritation
• Pruritus ani

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.